Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CAVR .007 20 mil os 8k -
found http://stockerlaw.com/ couldnt find carrera capital inc though
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 8, 2006
CARVER CORPORATION
(Exact name of registrant as specified in its chapter)
WASHINGTON
000-14482
91-1043157
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2425 East Camelback Road, Suite 1075, Phoenix, Arizona 85016
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 602-852-5445
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 1 -
SECTION 1 - REGISTRANT’S BUSINESS AND OPERATIONS
Item 1.01 - Entry into a Material Definitive Agreement
The undersigned believes that the registrant has not engaged in any material business operations for the last few years. The registrant has not filed the periodic reports required by the Securities and Exchange Commission since August, 1998. In addition, on or about July 31, 2005, the registrant’s corporate charter went into default with the Washington Secretary of State. Accordingly, it is believed that the registrant had abandoned its business.
Pursuant to its ORDER APPOINTING DAVID B. STOCKER AS CUSTODIAN OF CARVER CORPORATION dated August 8, 2006 (the “Order”), the Superior Court of Washington for Spokane County appointed David B. Stocker as custodian of the registrant, and authorized Mr. Stocker to take the following actions on behalf of the registrant:
•
Appoint new officers and board of directors for the registrant within 30 days of the Notice of Entry of the Order;
•
Reinstate the registrant’s articles of incorporation;
•
Locate the financial records of the registrant to file tax returns and information statements to permit it to resume its status of good standing;
•
Obtain copies of the registrant’s shareholders lists; and,
•
Any and all further actions on behalf of the registrant as permitted by the Court and the corporate laws of the State of Washington to otherwise restore the business and prospects of the registrant for the benefit of all shareholders of the registrant.
In accordance with the Order, Mr. Stocker appointed himself as sole interim director and president. In addition, the registrant hired Carrera Capital, Inc., a business consulting firm (“CCI”), for the purpose of assisting the registrant in its efforts to salvage value for the benefit of its shareholders. CCI has also agreed to advise the registrant as to potential business combinations. Mr. Stocker, an attorney, is the president of CCI.
As of September 6, 2006, CCI has contributed approximately $15,000 and obligated itself to contribute an additional $5,000 as paid in capital to the registrant. The registrant is to use these funds to pay the costs and expenses necessary to revive the registrant’s business operations. Such expenses include, without limitation, fees to reinstate the registrant’s corporate charter with the State of Washington, payment of all past due franchise taxes, settling all past due accounts with the registrant’s transfer agent, and accounting and legal fees. CCI has agreed to continue to contribute such additional funds as are necessary to accomplish these goals.
- 2 -
In consideration for these services and capital contribution(s), the registrant issued 10,300,000 shares of its common stock to CCI representing approximately 51.5% of its common stock outstanding as of September 6, 2006.
SECTION 3 - SECURITIES AND TRADING MARKETS
Item 3.02 - Unregistered Sale of Equity Securities
On September 6, 2006, the registrant issued to 10,300,000 shares of its common stock to CCI in exchange for $20,000. See Item 1.01 above.
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.01 - Changes in Control of Registrant
Pursuant to the Order and the arrangement with CCI, the registrant issued 10,300,000 shares of its common stock to CCI representing approximately 51.5% of the common stock outstanding as of September 6 2006. See Item 1.01, above.
Item 5.02 - Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Pursuant to the Order, David B. Stocker has been appointed sole director and officer of the registrant. See 1.01, above.
SECTION 8 - OTHER EVENTS
Item 8.01 - Other Events
At the direction of David B. Stocker, and as of this date, the registrant intends to update all regulatory filings and establish business operations that will enhance shareholder value.
- 3 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 6, 2006
CARVER CORPORATION
By: /s/ David B. Stocker
Name: David B. Stocker
Title: Interim Director
yup plus this guy seems determined to make somethin out of it: not to mention a shell w/20mil for .006?
http://stockerlaw.com/ like u said no brainer gl pdc :)
bastards forcing me to buy more @.006 :) lol
in CAVR -.009 ON SCAN AND TAKEOVER 8K BY SH HOLDER
nevermind, i dont know nor do i pretend to know ...shit!! hopefully its a pre cursur to tradin again if not f ck it ;) got us hopin again
hmm Mytrack started quoting bcit today - for months its been "not in database" w/ 0 balance in my acc
uhhmmm yes it is!!! an official filing would be nice,! ive owned ubal since may and ummmm if they reverse my shares they dam well better reverse they'rs !! if there is more than 200k os im sure the sec would be interested, nevada corp or not !
i think fvrd is stalling trying to figure out how to explain that ubal had 20 mil os did a 1-100 rs now fvrd has os of 20 mil ?? i think they forgot to fwd split my ubal sh before they rs'd em,bwtfdik
cinn sittin @15.12?4:07good sign bad sign?
yep in 2004 ford soldPi Group Ltd ::was purchased by 21st Century Racing LLC, a company owned by Kevin Kalkhoven and Gerry Forsythe. The change of ownership brings exciting new opportunities for Pi Research,
hmm yeah i just took the top 2 off google for the paragraph im still tryin to find the fancy shmancy snooper ware these guys are usin.!! guess aahhm not that thar intellergint yet :)
is it GT or LeClaire-ryan?
whew nwre !!! 11.06 got out just in time wahooo:)
nwre out 13.40 for now, nice weeks pay :)
mod , what broker?
nwre flyin now $13.23 :)
whew out acmg .085 takin the penny :)
ACMG .074 in big:) on news
ACMG news Alcar Chemicals Group Announces New $75M Contract
MONTREAL -- (MARKET WIRE) -- 07/05/06 -- Alcar Chemicals Group Inc. (PINKSHEETS
ACMG)
announces that it just closed a second contract with A-M Polymer Industries
Ltd. for $75M worth of polyols supplies.
M. Abbas Terki, following his return from Turkey -- where he successfully
negotiated a new polyester resin manufacturing facility to service the
growing demand for the Middle Eastern Market -- has signed a second 5 year
contract to secure the required raw materials supplies for its new facility
from ACMG.
The second A-M Polymer facility planned in Turkey will come online next
summer according to M. Terki and will require between 10,000 and 12,000
tons per annum of ethylene glycol and propylene glycol, the "green polyols"
manufactured by ACMG. "M. Terki had made me part of his plans and I knew
that A-M Polymer was in full expansion, especially with its recent
homologations for construction and naval applications, but I didn't expect
such an additional contract this fast," said Alexander Cavasin, CEO of
Alcar Chemicals Group. "I will be meeting M. Terki next week in Geneva to
propose a single contract to include supply scheduling for both facilities.
The production of 20,000 tons annually will require three reactors, A-M
polymer will have to work with us on a ramp-up schedule as to avoid any
shortages; I agree it is a nice problem to have, nonetheless, it requires
extra planning and additional funds to respond to the increased demand,"
further added Dr. Cavasin.
Under the present conditions the combined contracts are worth $158M dollars
over a five year period, or $31.6M annually in sales revenues and royalties
combined. "Our updated Business Plan, including financials and revised
projections, are now available online through our website," specified Dr.
Cavasin when asked about more details.
About Alcar Chemicals Group
The Alcar Chemicals Group (PINKSHEETS: ACMG) represents a significant
market opportunity due to a serious worldwide supply shortage of raw
materials for polymers as well as an increased requirement for ethanol and
biodiesel. ACMG has been concentrating on innovative methods for biomass
valorisation for the past decade, specifically petroleum-independent fuel
and plastics resin production. Its proprietary technology represents
today's most economical and advanced manufacturing process for plastic raw
materials, ethanol and bio-diesel, allowing production at cost savings of
up to 40% when compared to current production methods.
To hear more about ACMG from Alexander P. Cavasin go to:
http://www.publiccoreport.net/featured/ACMG/company.asp
Important Information About Forward-Looking Statements
All statements and information in this news release, other than historical
facts, are forward-looking statements, which contain our current
expectations about our future results. Forward-looking statements involve
numerous risks and uncertainties which are subject to section 27A of the
Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are
subject to safe harbor created by these sections. We have attempted to
identify any forward-looking statements by using words such as
"anticipates," "believes," "could," "expects," "intends," "may," "should"
and other similar expressions. Although we believe that the expectations
reflected in all of our forward-looking statements are reasonable, we can
give no assurance that such expectations will prove to be correct and
actual results may vary.
A number of factors may affect our future results and may cause those
results to differ materially from those indicated in any forward-looking
statements made by us or on our behalf. Such factors include our limited
operating history; our need for significant capital to finance internal
growth as well as strategic acquisitions; our ability to attract and retain
key employees and strategic partners; our ability to achieve and maintain
profitability; fluctuations in the trading price and volume of our stock;
competition from other providers of similar products and services; and
other unanticipated future events and conditions.
Contact Info:
Homer Pateridis
Investor relations consultant
Tel 514-952-5251
homer@alcarchemicalsgroup.com
www.AlcarChemicalsGroup.com
*** end of story ***
i aint marrying it :) we're just dating right now
npyc .13x.19 nice action today
NWRE COMIN UP ON $13. TOOK A WHILE BUT BOUNCIN NIIICELY
added more nwre 12.00 saw 150k trade go thru
NWRE in @$12.80 playin a little pre mkt bounce
NPYC .15 grabbed a few on buyout news
lol me too ,whatever grabbed a few fer shits n giggles anyway thanx wayne
question on npyc, is the 35 mil for patents "after closing" in addition to the 50 mil buyout? tia still tryin to learn to read :)
from ez's board ,great info, he's closin up so i thought id save the great info from his i box
I look for companies with good news; near the bottom of the
charts. Look for reversal plays, breakouts and gappers.
My pick or any other...please DD before you buy.
Due Diligence
Researching threads to find them:
Filings
http://www.pinksheets.com/
http://www.atedgar.com/
http://www.otcbb.com/dynamic/update_2003.htm
Chartshttp://bigcharts.marketwatch.com/default.asp?
http://stockta.com/
News
http://www.allstocks.com/html/news_pages.html
http://home.businesswire.com/portal/site/home/index.jsp?front_door=true
Stock Screeners
http://stockcharts.com/def/servlet/SC.scan
http://clearstation.etrade.com/redge.html
http://screener.finance.yahoo.com/newscreener.html
http://smallcapcenter.com/tools_tools.asp
http://finance.yahoo.com/
http://www.earningswhispers.com/
http://www.tradersnotebook.com/mrktmkrs.html
http://www.otcbbtrader.com/portal/goto.dll
Suggested Stock Broker: Ameritrade.
A good place to visit and watch your favorite boards:
http://www.investorshub.com/boards/top_boards.asp
Archangel's Scrapple Board
This board contains links for almost any need or subject, thousands of links here.
http://www.investorshub.com/boards/board.asp?board_id=474
Eligibility Rules
http://www.otcbb.com/news/eligibilityrule/noncompl_procs.stm
Stock Market Holiday Schedule
http://www.allstocks.com/html/stock_markets_holidays.html
Archive of Penny Stock News
http://www.allstocks.com/homepages/homepage6.htm
Daily Changes
http://www.pinksheets.com/marketactivity/venue_changes.jsp
Trading Statistics
http://www.pinksheets.com/marketactivity/trade_stats.jsp
EZ's S-8 board...the number #1 rated search on Yahoo:
http://www.investorshub.com/boards/board.asp?board_id=1605
http://search.yahoo.com/search?p=s-8&fr=FP-tab-web-t&toggle=1&cop=&ei=UTF-8
A good read posted by glassy:
http://www.investorshub.com/boards/read_msg.asp?message_id=5532366
A definite recommendation by EZ for F/T traders:
http://www.microcaptrade.com/index.html
Examples of trading rooms:
http://www.trading-naked.com/TradingRooms.htm
Patience Definition:
Patience (Pa"tience) (?), n.
[F. patience, fr. L. patientia. See Patient.]
1. The state or quality of being patient; the power of suffering with fortitude; uncomplaining endurance of evils or wrongs, as toil, pain, poverty, insult, oppression, calamity, etc. "Strenthened with all might, . . . unto all patience and long-suffering." Col. i. 11. "I must have patience to endure the load." Shak. "Who hath learned lowliness From his Lord's cradle, patience from his cross." Keble.
2. The act or power of calmly or contentedly waiting for something due or hoped for; forbearance. "Have patience with me, and I will pay thee all." Matt. xviii. 29.
3. Constancy in labor or application; perseverance. "He learned with patience, and with meekness taught." Harte.
4. Sufferance; permission. [Obs.] Hooker. "They stay upon your patience." Shak.
5. (Bot.) A kind of dock (Rumex Patientia), less common in America than in Europe; monk's rhubarb.
6. (Card Playing) Solitaire.
Synonyms -- Patience, Resignation. Patience implies the quietness or self-possession of one's own spirit under sufferings, provocations, etc.; resignation implies submission to the will of another. The Stoic may have patience; the Christian should have both patience and resignation.
Remember: Know What You Own and Patience Pays.
"The stock market is a vehicle to move WEALTH from the impatient to the patient."
SHO LIST
http://www.nasdaqtrader.com/aspx/regsho.aspx
Cool songs and more visit wantoberich at:
#board-1654
#board-3912
Good Luck to All. EZ.
lol you got it :)alarm is set
reduced to just a sliver of his former self ohhh- alas poor splinter ..err bob we knew him well...
poor bob was found with a huge................
smile on his face whatta way to go rip brudda:)
hey, you broke outa jail !!
lol :) add " GOT WOOD ? " ;)
aka "Woody" Planck ,along with his brothers notty &crooked ,wrote a warped pulp fiction novel - The planer side of quantum physics/leaving the 4th dimension
dont worry mike u r the FISHER KING !!
siga $1.30 merger w/pharmathene (COMTEX) B: PharmAthene and SIGA Technologies Sign Definitive Merger Agree
ent to Establish Premier Biodefense Company ( Busines
B: PharmAthene and SIGA Technologies Sign Definitive Merger Agreement to Establi
h Premier Biodefense Company ( BusinessWire )
ANNAPOLIS, Md. & NEW YORK, Jun 09, 2006 (BUSINESS WIRE) --
PharmAthene, Inc. and SIGA Technologies, Inc. (NASDAQ:
SIGA) announced today that they have signed a definitive agreement
providing for the merger of PharmAthene and SIGA. The combined
company, which will operate under the "PharmAthene" name, will be a
leader in biodefense featuring a substantial portfolio of
procurement-stage biodefense products targeting anthrax, smallpox and
chemical nerve agents, as well as a robust pipeline of therapeutic and
prophylactic drug candidates targeting Category A biowarfare agents
and emerging infectious diseases.
"A strategic merger with SIGA significantly advances our strategy
of building a leading biodefense company with a comprehensive
portfolio of medical countermeasures to meet the urgent needs of our
Nation and Allies," said David P. Wright, President and Chief
Executive Officer of PharmAthene. "Combining PharmAthene's strong
development and commercialization capabilities and procurement-stage
biodefense products with SIGA's procurement-stage smallpox antiviral
treatment, ST-246, and exceptional research pipeline, establishes a
premier biodefense organization with multiple procurement-stage
products with near-term revenue potential, and a broad research
pipeline focused on biodefense and emerging infectious diseases."
"Following the merger, our biodefense portfolio will include
procurement-stage products targeting three of the top five priorities
under Project BioShield," said Mr. Wright. Included in this portfolio
are:
-- ST-246, a small molecule orally-active antiviral therapeutic
for the treatment of smallpox and other orthopox virus
infections.
-- Valortim(TM), a fully human monoclonal antibody being
co-developed with Medarex (NASDAQ: MEDX) for the prevention
and treatment of anthrax infection.
-- Protexia(R) a novel bioscavenger to prevent and treat
organophosphate nerve agent poisoning.
"Recently, both Valortim(TM) and ST-246 have made important
clinical progress," continued Mr. Wright. "Phase I clinical testing of
Valortim(TM) in healthy volunteers to evaluate safety and dose
response has recently been completed. Detailed results from the study
are planned for release later this year. SIGA recently commenced a
Phase I study of ST-246 in healthy volunteers, which is expected to be
completed shortly. Preclinical studies of Valortim(TM) and ST-246 have
previously demonstrated efficacy in animal models. If the Phase I
results support safety in humans, then we expect that Valortim(TM) and
ST-246 should be promising candidates for procurement consideration
for the Strategic National Stockpile."
Donald Drapkin, Chairman of the Board of SIGA, commented, "We see
this strategic merger with PharmAthene as a tremendous opportunity for
our Company and our shareholders. PharmAthene brings a management team
that is highly experienced in identifying niche markets, developing
drugs to address those markets, and launching successful products that
dominate their respective therapeutic classes. We are confident in
their ability to generate tremendous value for our shareholders, while
providing the necessary vision and leadership to drive future growth."
The merger agreement, which has been unanimously approved by the
Boards of Directors of both companies, is subject to shareholder and
regulatory approval, the completion of a financing transaction, and
other customary closing conditions, and is expected to close in the
third quarter. David P. Wright, President and Chief Executive Officer
of PharmAthene, will serve as President and Chief Executive Officer of
the combined company. WR Hambrecht + Co and Sutter Securities
Incorporated acted as financial advisors to PharmAthene and SIGA,
respectively.
This communication is being made in respect of the proposed merger
transaction involving SIGA Technologies, Inc. and PharmAthene, Inc.
SIGA will promptly file with the SEC a current report on Form 8-K,
which will include the merger agreement and related documents. In
addition, SIGA will file a proxy statement with the SEC in connection
with the transaction and mail the final proxy statement to SIGA
shareholders of record at the record date for the special meeting of
the shareholders to be held to provide approvals relating to the
proposed transaction. The proxy statement that SIGA plans to file with
the SEC and mail to its shareholders will contain information about
SIGA, PharmAthene, the proposed merger, and related matters.
SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY WHEN IT
IS AVAILABLE, AS IT WILL CONTAIN IMPORTANT INFORMATION THAT
SHAREHOLDERS SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT THE
MERGER. In addition to receiving the proxy statement and proxy card by
mail, shareholders will also be able to obtain the proxy statement, as
well as other filings containing information about SIGA, without
charge, from the SEC's website (http://www.sec.gov) or, without
charge, by contacting Thomas Konatich at SIGA at (212) 672-9100. This
announcement is neither a solicitation of proxy, an offer to purchase,
nor a solicitation of an offer to sell shares of SIGA.
SIGA and its executive officers and directors may be deemed to be
participants in the solicitation of proxies from SIGA's shareholders
with respect to the matters relating to the proposed merger.
PharmAthene may also be deemed a participant in such solicitation.
Information regarding SIGA's executive officers and directors is
available in SIGA's Annual Report on Form 10-K, for the year ended
December 31, 2005. Information regarding any interest that PharmAthene
or any of the executive officers or directors of PharmAthene may have
in the transaction with SIGA will be set forth in the proxy statement
that SIGA intends to file with the SEC in connection with the matters
to be approved in connection with the proposed merger. Shareholders of
SIGA can obtain this information by reading the proxy statement when
it becomes available.
About PharmAthene, Inc.
PharmAthene, a privately-held biotechnology company, was formed to
meet the critical needs of the United States by developing biodefense
products. PharmAthene is dedicated to the rapid development of
important and novel biotherapeutics to address biological pathogens
and chemicals that may be used as weapons of bioterror. PharmAthene's
lead programs include Valortim(TM) (being co-developed with Medarex
(NASDAQ:MEDX)) and Protexia. PharmAthene is located in the Chesapeake
Innovation Center in Annapolis, MD, the first technology incubator
focused solely on Homeland Security. PharmAthene has been successful
in obtaining U.S. Government and Venture Capital funding to finance
the development of its portfolio products. For more information on
PharmAthene, please visit its website at www.PharmAthene.com.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and
sophisticated computational modeling in the design and development of
novel products for the prevention and treatment of serious infectious
diseases, with an emphasis on products for biological warfare defense.
SIGA's product development programs emphasize the increasingly serious
problem of drug resistant bacteria. In addition to smallpox, SIGA has
antiviral programs targeting other Category A viral pathogens,
including arenaviruses (Lassa Fever Virus, Junin, Macupo, Guanarito,
and Sabia), Lymphocytic choriomeningitis virus (LCMV), Dengue, the
filoviruses, Ebola and Marburg. For more information about SIGA,
please visit SIGA's Web site at www.siga.com.
Forward Looking Statement Disclosure
This press release contains certain "forward-looking statements''
within the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including statements regarding the efficacy of
potential products, the timelines for bringing such products to
market, for achieving regulatory approval, the government procurement
process, the release of clinical data, and the availability of funding
sources for continued development of such products. Forward-looking
statements are based on management's estimates, assumptions and
projections, and are subject to uncertainties, many of which are
beyond the control of SIGA and PharmAthene. Actual results may differ
materially from those anticipated in any forward-looking statement.
Factors that may cause such differences include the risks that (a)
there may be regulatory or litigation obstacles to completing the
merger, (b) shareholders of one or both companies may not approve the
merger, (c) the NASDAQ market may not accept the shares of the merged
company for continued listing, (d) products under investigation by
SIGA or PharmAthene cannot be shown to be efficacious or safe in
subsequent preclinical or clinical trials, (e) SIGA, PharmAthene or
their collaborators will not obtain appropriate or necessary
governmental approvals to market their products, (f) SIGA or
PharmAthene may not be able to obtain anticipated funding for their
development projects or other needed funding, (g) SIGA or PharmAthene
may not be able to secure funding from anticipated government
contracts and grants, and (h) SIGA or PharmAthene may not be able to
secure or enforce adequate legal protection, including patent
protection, for their products.
More detailed information about SIGA and risk factors that may
affect the realization of forward-looking statements, including the
forward-looking statements in this press release is set forth in
SIGA's filings with the Securities and Exchange Commission, including
SIGA's Annual Report on Form 10-K for the fiscal year ended December
31, 2005, and in other documents that SIGA has filed with the
Commission. SIGA urges investors and security holders to read those
documents free of charge at the Commission's Web site at
http://www.sec.gov. Interested parties may also obtain those documents
free of charge from SIGA. Forward-looking statements speak only as to
the date they are made, and, except for any obligation under the U.S.
federal securities laws, SIGA undertakes no obligation to publicly
update any forward-looking statement as a result of new information,
future events or otherwise.
SOURCE: SIGA Technologies, Inc.
For PharmAthene, Inc.:
Stacey Jurchison, 410-571-8925
jurchisons@pharmathene.com
or
For SIGA Technologies, Inc.:
Thomas N. Konatich, 212-672-9100
tkonatich@siga.com
Copyright Business Wire 2006
**********************************************************************
As of Monday, 06-05-2006 23:59, the latest Comtex SmarTrend(SM) Alert,
an automated pattern recognition system, indicated an UPTREND on
09-27-2005 for SIGA @ $1.25.
(C) 2006 Comtex News Network, Inc. All rights reserved.
*** end of story ***
i think penson is waitin for delivery to quote again
i just hope mytrack starts quoting again sucks w a mill sh and 0 balance in my acc
strange mytrack has bcit as not valid symbol 1st time since this whole thing started and valued @ 0 still shows my sh# in my acc tho